110448-33-4 Usage
Description
ML-7 HYDROCHLORIDE, also known as ML-7, is a potent and selective inhibitor of myosin light chain kinase (MLCK). It is an off-white to yellow fine crystalline solid that inhibits smooth muscle MLCK with a Ki value of 0.3 μM. ML-7 displays reversible, ATP-competitive inhibition of both Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs and is 10 times more potent than its parent compound ML-9.
Uses
Used in Research Applications:
ML-7 HYDROCHLORIDE is used as a research tool for studying the role of MLCK in various cellular processes and diseases. Its potent and selective inhibition of MLCK makes it a valuable compound for investigating the molecular mechanisms underlying smooth muscle contraction, cell migration, and signal transduction pathways.
Used in Pharmaceutical Industry:
ML-7 HYDROCHLORIDE is used as a lead compound in the development of new drugs targeting MLCK for the treatment of various diseases, such as hypertension, asthma, and other conditions involving smooth muscle dysfunction.
Used in Drug Delivery Systems:
ML-7 HYDROCHLORIDE can be incorporated into drug delivery systems to improve its bioavailability, stability, and targeted delivery to specific tissues or cells. This can enhance the therapeutic efficacy of ML-7 and reduce potential side effects.
Biochem/physiol Actions
Selective myosin light chain kinase inhibitor.
in vitro
rats with myocardial infarction were intravenously infused with rhnrg-1. the cmlck expression and phosphorylated mlc-2v were up-regulated in rat treated with rhnrg-1 significantly. moreover, the restoration of rhnrg-1-induced sarcomeric organization in serum-free cultured neonatal rat cardiomyocytes with rhnrg-1 was inhibited by ml-7 [1].
in vivo
administration of ml-7 from 10 min before ischemia to the first 10 min of reperfusion led to a significant recovery of heart contractility. gel analyses of two-dimensional electrophoresis revealed eight proteins with decreased levels in i/r hearts. six proteins involved in energy metabolism, which were cytochrome b-c1 complex subunit 1, atp synthase beta subunit, cytochrome c oxidase subunit, mitochondrial nadhdehydrogenase, nadhdehydrogenase iron-sulfur protein 8, and succinyl-coa ligase subunit. the other two protein levels decreased in i/r hearts, which were peroxiredoxin-2 and tubulin. in addition, ml-7 treatment increased the level of succinyl-coa ligase, which was a key enzyme involved in the citric acid cycle [2].
references
[1] gu x,liu x,xu d,li x,yan m,qi y,yan w,wang w,pan j,xu y,xi b,cheng l,jia j,wang k,ge j,zhou m. cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. cardiovasc res.2010 nov 1;88(2):334-43. [2] lin hb,cadete vj,sawicka j,wozniak m,sawicki g. effect of the myosin light chain kinase inhibitor ml-7 on the proteome of hearts subjected to ischemia-reperfusion injury. j proteomics.2012 sep 18;75(17):5386-95.
Check Digit Verification of cas no
The CAS Registry Mumber 110448-33-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,4,4 and 8 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 110448-33:
(8*1)+(7*1)+(6*0)+(5*4)+(4*4)+(3*8)+(2*3)+(1*3)=84
84 % 10 = 4
So 110448-33-4 is a valid CAS Registry Number.
